StemCyte Announces Successful Outcome in Phase I Clinical Trial for Treating Acute Cerebral Stroke Using Allogeneic Human Umbilical Cord Blood
BALDWIN PARK, Calif., Jan. 26, 2022 /PRNewswire/ -- Southern California cord blood therapeutics company StemCyte Inc. is announcing successful pre...
Source: businessinsider.com